Back to top

Image: Bigstock

Collegium Pharmaceutical (COLL) Q2 Earnings: How Key Metrics Compare to Wall Street Estimates

Read MoreHide Full Article

Collegium Pharmaceutical (COLL - Free Report) reported $145.28 million in revenue for the quarter ended June 2024, representing a year-over-year increase of 7.2%. EPS of $1.62 for the same period compares to $1.26 a year ago.

The reported revenue represents a surprise of +1.08% over the Zacks Consensus Estimate of $143.73 million. With the consensus EPS estimate being $1.56, the EPS surprise was +3.85%.

While investors closely watch year-over-year changes in headline numbers -- revenue and earnings -- and how they compare to Wall Street expectations to determine their next course of action, some key metrics always provide a better insight into a company's underlying performance.

Since these metrics play a crucial role in driving the top- and bottom-line numbers, comparing them with the year-ago numbers and what analysts estimated about them helps investors better project a stock's price performance.

Here is how Collegium Pharmaceutical performed in the just reported quarter in terms of the metrics most widely monitored and projected by Wall Street analysts:

  • Total product revenues- Belbuca

    : $52.20 million versus $50.02 million estimated by four analysts on average. Compared to the year-ago quarter, this number represents a +21% change.
  • Total product revenues- Nucynta

    : $44.48 million versus $44.42 million estimated by four analysts on average. Compared to the year-ago quarter, this number represents a -6% change.
  • Total product revenues- Symproic

    : $4.03 million versus the four-analyst average estimate of $3.89 million. The reported number represents a year-over-year change of +5.1%.
  • Total product revenues- Xtampza ER

    : $44.57 million compared to the $46.14 million average estimate based on four analysts. The reported number represents a change of +8.1% year over year.
View all Key Company Metrics for Collegium Pharmaceutical here>>>

Shares of Collegium Pharmaceutical have returned +10.4% over the past month versus the Zacks S&P 500 composite's -6.5% change. The stock currently has a Zacks Rank #3 (Hold), indicating that it could perform in line with the broader market in the near term.

See More Zacks Research for These Tickers


Normally $25 each - click below to receive one report FREE:


Collegium Pharmaceutical, Inc. (COLL) - free report >>

Published in